Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 13, Issue 12, Pages 1399-1408Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2013.856761
Keywords
IMA901; immune therapy; renal cell carcinoma; tumor associated antigen; tumor microenvironment; tyrosine-kinase inhibitor; vaccination
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [SFB 685 C5]
Ask authors/readers for more resources
Immunotherapy with cytokines was the first effective treatment in metastatic renal cell carcinoma (mRCC). Long-term responders and complete remissions were observed, but efficacy in the overall population was limited with the consequence that targeted agents replaced cytokines. The discovery of tumor associated antigens as direct targets paved the way from theses rather unspecific to specific immunotherapeutic strategies, which are discussed in this review. Autologous or dendritic cell (DC) based tumor vaccination with vitespen or AGS-003, adoptive T-cell transfer and synthetic peptide vaccination with IMA901 are new and promising approaches. Besides that the more passive strategies of antibody dependent cytotoxicity with the VEGF antibody bevacizumab or the carbonic anhydrase IX antibody girentuximab are discussed. Immunomodulation by cyclophosphamide, tyrosine kinase inhibitors or nivolumab, which targets the PD-1 axis, further promote T-cell activation and combinatory strategies with these agents are outlined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available